DEPT LOGO

 Home Page
 Department Divisions
 Personnel
 Brochures & Newsletters
 Clin. Training Programs
 Res. Training Programs
 Consultation Services
 Case Studies
 Case of the Month
 Online CME
 Seminars
 Residents Web
 Feedback
 Links
 Links


Department of Pathology
University of Pittsburgh
School of Medicine
S-417 BST
200 Lothrop Street
Pittsburgh, PA 15261
(412) 648-1260
v-line

Department of Pathology - Faculty

W. Tony Parks, M.D.

Dr. Bhargava

Dr. Bhargava received his Bachelor of Medicine and Bachelor of Surgery (MBBS) degree from the SMS Medical College of Rajasthan University (Jaipur, India). Upon arrival in the United States in 1998, he underwent residency training in Anatomic and Clinical Pathology at Baystate Medical Center (Western Campus of Tufts University) in Springfield, Massachusetts followed by fellowship training in Oncologic Surgical Pathology and Diagnostic Molecular Pathology at Memorial Sloan-Kettering Cancer Center in New York, NY. He has been a faculty member at Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) since September 2004. Dr. Bhargava is currently an Associate Professor of Pathology at the University of Pittsburgh, School of Medicine. He serves as Co-Director of Surgical Pathology at Magee-Womens Hospital. He is also the Medical Director of the Histotechnology School at UPMC.

Office Location:

Department of Pathology
Magee-Womens Hospital
300 Halket Street
Pittsburgh, PA 15213

 Contact Information:

Office Phone: (412) 641-4641
Email Address: rbhargava@mail.magee.edu

Research Interests:

Dr. Bhargava's main research interest and clinical expertise is within the field of breast cancer. He is a recipient of the prestigious Stephen Vogel award of the United States and Canadian Academy of Pathology. His research interests include identifying novel diagnostic and prognostic markers for invasive and in situ breast cancer, study of predictive biomarkers in breast carcinoma and their correlation to clinical outcome. He also has an interest in identifying site of origin for "carcinoma of unknown primary" using immunohistochemistry and other ancillary techniques.

Selected Publications:

  1. High false-negative rate of HER2 qRT-PCR of the Oncotype DX test: An independent quality assurance study. David J. Dabbs, Molly Klein, Syed Mohsin, Raymond R. Tubbs, and Rohit Bhargava. J Clin Oncol. 2011;29:4279-4285.
  2. Pathology of breast carcinoma: diagnostic, prognostic, and therapeutic issues and challenges. Bhargava R, Sahoo S, Esposito NN, Chen B. Patholog Res Int. 2011;2011:73140.
  3. MRI staging after neoadjuvant chemotherapy for breast cancer: Does tumor biology affect accuracy? Kandace P. McGuire, MD, Jorge Toro-Burguete, MD, Hang Dang, DO, Jessica Young, MD, Atilla Soran, MD, MPH, Margarita Zuley, MD, Rohit Bhargava, MD, Marguerite Bonaventura, MD, Ronald Johnson, MD, Gretchen Ahrendt, MD. Ann Surg Oncol. 2011;18:3149-3154.
  4. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract and other CK7 positive carcinomas: Potential use for determining site of origin. Anna H Woodard M.D., Jing Yu M.D., David J Dabbs M.D., Sushil Beriwal M.D., Anca V Florea M.D., Esther Elishaev, M.D., Jon M Davison M.D., Alyssa M Krasinskas M.D., and Rohit Bhargava M.D. Am J Clin Pathol. 2011;136:428-435.
  5. Molecular Class as a Predictor of Locoregional and Distant Recurrence in the Neoadjuvant Setting for Breast Cancer. Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R. Oncology 2011;80:341-349. http://content.karger.com/ProdukteDB/produkte.aspDOI=10.1159/000330203
  6. Classical Type Invasive Lobular Carcinoma with HER2 Overexpression: Clinical, Histological and Hormone Receptor Characteristics. Jing Yu, MD, PhD, David J. Dabbs, MD, Yongli Shuai, MS, Leo A. Niemeier, MD, Rohit Bhargava, MD. Am J Clin Pathol. 2011 Jul;136(1):88-97.
  7. MicroRNA analysis in human papillomavirus (HPV)-associated cervical neoplasia and cancer. Amy S Gardiner, William C McBee, Jr., Robert P Edwards, Marshall Austin, Jamie L Lesnock, Rohit Bhargava, Richard Guido, and Saleem A Khan. Infectious Agents and Cancer 2010 5(Suppl 1):A55.
  8. Intracystic papillary carcinomas of the breast are more similar to in-situ carcinomas than invasive carcinoma. Rohit Bhargava, M.D., Nicole N. Esposito, M.D., David J. Dabbs, M.D. Am J Surg Pathol. 2011;35:778-779.
  9. Insulin-Like Growth Factor Receptor-1 (IGF-1R) Expression In Normal Breast, Proliferative Breast Lesions And Breast Carcinoma. Rohit Bhargava M.D., Sushil Beriwal, M.D., Kim McManus, HT (ASCP), David J Dabbs, M.D. Appl Immunohistochem Mol Morphol. 2011;19:218-225.
  10. Semiquantitative hormone receptor level influences response to trastuzumab containing neoadjuvant chemotherapy in HER2 positive breast cancer. Rohit Bhargava, M.D., David J. Dabbs, M.D., Sushil Beriwal, M.D., Isil A. Yildiz, M.D., Preeti Badve, Atilla Soran, M.D., Ronald R. Johnson, M.D., Adam M. Brufsky, M.D., Barry C. Lembersky, M.D., Kandace McGuire, M.D., and Gretchen M. Ahrendt, M.D. Accepted to be published in Mod Pathol. 2011;24:367-374.
  11. Differential Proteomic Analysis of Late-Stage and Recurrent Breast Cancer from Formalin-Fixed Paraffin-Embedded Tissues. Bateman, Nicholas; Sun, Mai; Bhargava, Rohit; Hood, Brian; Darfler, Marlene; Kovatich, Albert; Hooke, Jeffrey; Krizman, David; Conrads, Thomas. Accepted for publication in J Proteome Res. 2011;10:1323-1332.
  12. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Vera S. Donnenberg, Ph.D., Albert D. Donnenberg, Ph.D. Ludovic Zimmerlin, Rodney J. Landreneau, M.D., Rohit Bhargava, M.D., Ryan A. Wetzel1, Per Basse, and Adam M. Brufsky, M.D. Cytometry B Clin Cytom. 2010 Sep;78(5):287-301.
  13. Letter Regarding Ibarra et al article titled "Fixation time does not affect the expression of estrogen receptor (Am J Clin Pathol. 2010; 133:747-755)". Am J Clin Pathol. 2011 Jan;135(1):171-2. David J Dabbs, M.D. and Rohit Bhargava, M.D.
  14. Spatial-domain low-coherence quantitative phase microscopy for cancer diagnosis. Wang P, Bista R, Bhargava R, Brand RE, Liu Y. Opt Lett. 2010; 35(17):2840-2842.
  15. Expression Analysis of Ubc9, the Single SUMO E2 Conjugating Enzyme, in Normal and Malignant Tissues. Stergios Moschos, Drazen M. Jukic, Charalambos Athanassiou, Rohit Bhargava, Shih-Fan Kuan, Sanja Dacic, Shelley L. Fayewicz, Marie Acquafondata, Rajiv Dhir. Hum Pathol. 2010;41:1286-98.
  16. Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies. Jing Yu, Rohit Bhargava and David J Dabbs. Diagnostic Pathology. 2010;5:36.
  17. Assessment of Buffer Systems for Harvesting Proteins from Tissue Interstitial Fluid for Proteomic Analysis. Teng, Pang-ning; Rungruang, Bunja; Hood, Brian; Sun, Mai; Flint, Melanie; Bateman, Nicholas; Dhir, Rajiv; Bhargava, Rohit; Richard, Scott; Edwards, Robert; Conrads, Thomas. Journal of Proteome Research. 2010;9:4161-4169.
  18. Metastatic Ovarian Serous Carcinoma Presenting as Inflammatory Breast Cancer: A Case Report. Dana Gingell, Amber Samuel, Denise Haynik, William McBee, Joseph Kelley, Kristen Zorn, Rohit Bhargava. Int J Gynecol Pathol. 2010;29:243-247.
  19. Concordance Between Semiquantitative Immunohistochemical Assay and Oncotype DX RT-PCR Assay for Estrogen and Progesterone Receptors. Siobhan O'Connor, David J Dabbs, Sushil Beriwal, Rohit Bhargava. Appl. Immunohistochem Mol Morphol. 2010;18:268-272.
  20. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: A single institutional experience with 359 cases. Rohit Bhargava, M.D., Sushil Beriwal, M.D., David J. Dabbs, M.D., Umut Ozbek, M.S., Atilla Soran, M.D., Ronald R. Johnson, M.D., Adam M. Brufsky, M.D., Barry C. Lembersky, M.D., Gretchen M. Ahrendt, M.D. Cancer. 2010;116:1431-1439.
  21. Androgen Receptor in Breast Cancer: Expression in Estrogen Receptor Positive Tumors and in Estrogen Receptor Negative Tumors with Apocrine Differentiation. Leo A. Niemeier, David J Dabbs, Sushil Beriwal, Joan Striebel, Rohit Bhargava. Mod Pathol. 2010;23:205-212.
  22. Breast Cancer Molecular Class ERBB2: Preponderance Of Tumors With Apocrine Differentiation And Expression Of Basal Phenotype Markers CK5, CK5/6 And EGFR. Rohit Bhargava, Sushil Beriwal, Joan Striebel, David J Dabbs. Appl Immunohistochem Mol Morphol. 2010;18:113-118.
  23. Biomarker profile in breast carcinomas presenting with bone metastasis. Olga L. Bohn, Irem Nasir, Adam Brufsky, George C Tseng, Rohit Bhargava, Kim McManus, Mamatha Chivukula. Int J Clin Exp Pathol 2010;3(2):139-146.
  24. Comparison of Locoregional Recurrence with Mastectomy vs. Breast Conserving Surgery in Pregnancy Associated Breast Cancer (PABC). Sushil Beriwal, Bunja Rungruang, Atilla Soran, Darcy Thull, Joseph L Kelley, Rohit Bhargava, Chyongchiou J. Lin, Paniti Sukumvanich. Cancers. 2009, 1(1), 12-20; doi:10.3390/cancers1010012
  25. A Quantitative Reverse Transcription-PCR Assay for Rapid Automated Analyses of Breast Cancer Sentinel Lymph Nodes. Hughes SJ, Xi, L, Gooding WE, Cole DJ, Mitas M, Metcalf J, Bhargava R, Dabbs D, Ching J, Kozma L, McMillan W, Godfrey TE. J Mol. Diagn. 2009;11:576-582.
  26. PAX2: a novel müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma Mamatha Chivukula, David J Dabbs, Siobhan O'Connor, Rohit Bhargava. Int J Gynecol Pathol. 2009;28:570-578.
  27. Thyroid transcription factor-1 and "basal-marker" expressing small cell carcinoma of the breast. Cagatay Ersahin, Sudeshna Bandyopadhyay, and Rohit Bhargava. Int J Surg Pathol. 2009;17:368-372.
  28. Clinicopathologic Implications of 'Flat Epithelial Atypia' on Core Needle Biopsies of Breast. Mamatha Chivukula, Rohit Bhargava, David J Dabbs. Accepted to be published in Am J Clin Pathol. 2009;131:802-808.
  29. Basal-like Subtype Breast Cancers in Women Older than 40 Years of Age. Cagatay Ersahin, Mamatha Chivukula, Rohit Bhargava, David J Dabbs. Int J Surg Pathol. 2010;18:42-47.
  30. Intraductal location of the sclerosing adenosis of the breast. Bulent Unal, A Serhat Gur, Rohit Bhargava, Howard Edington, Gretchen Ahrendt, Atilla Soran. Bratisl Lek Listy. 2009;11(4):251-252.
  31. Prevalence, Morphologic Features and Proliferation Indices of Breast Carcinoma Molecular Classes Using Immunohistochemical Surrogate Markers. Rohit Bhargava, Joan Striebel, Sushil Beriwal, John C. Flickinger, Agnieszka Onisko, Gretchen Ahrendt and David J. Dabbs. Int J Clin Exp Pathol 2009;2(5):444-455.
  32. Are encapsulated papillary carcinomas of the breast in-situ or invasive? A basement membrane study of 27 cases. Nicole N Esposito, David J Dabbs, Rohit Bhargava. Am J Clin Pathol. 2009;131:228-242.
  33. CK5 is more sensitive than CK5/6 in identifying "basal-like" phenotype of breast carcinoma. Rohit Bhargava, M.D. Sushil Beriwal, M.D. Kim McManus, M.D. David J Dabbs, M.D. Am J Clin Pathol. 2008;130:724-730.
  34. Luminal B tumors are not HER2 positive. Rohit Bharagva and David J Dabbs. Breast Cancer Research. 2008;10:404.
  35. Estrogen and Progesterone Receptors in Breast Carcinoma: Quantitation is Therapeutically Important. Rohit Bhargava, M.D., Mamatha Chivukula, M.D., Sushil Beriwal, David J. Dabbs, M.D. Adv Anat Pathol. 2008 Sep;15(5):304-305.
  36. Diagnostic, Theranostic and Genomic Immunohistochemistry: Standardization Issues. Mamatha Chivukula, M.D., Rohit Bhargava, M.D., David J. Dabbs, M.D. Adv Anat Pathol. 2008 Sep;15(5):302-304.
  37. Mammaglobin Expression In The Female Genital Tract: Immunohistochemical Analysis in Benign and Neoplastic Endocervix and Endometrium. Kazuya Onuma, David J Dabbs, Rohit Bhargava. Int J of Gynecol Pathol. 2008;27:418-425.
  38. WT-1 immunoreactivity in breast carcinoma: Selective expression in pure and mixed mucinous subtypes. Akosua B Domfeh, AnnaMarie L Carley, Joan M Striebel, Rouzan G Karabakhtsian, Anca V Florea, Kim McManus, Sushil Beriwal and Rohit Bhargava. Mod Pathol. 2008;21:1217-1223.
  39. Histopathologic Variables Predict Oncotype DX™ Recurrence Score. Melina B. Flanagan, MD, MSPH, David J. Dabbs, MD, Adam Brufsky, MD, PhD, Sushil Beriwal, MD, Rohit Bhargava, MD. Mod Pathol. 2008;21:1255-1261.
  40. Clinical importance of HER2 immunohistologic heterogenous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ. Mod Pathol. 2008;21:363-368.
  41. The Equivocally Amplified HER2 FISH Result on Breast Core Biopsy: Indications for Further Sampling Do Affect Patient Management. Joan M. Striebel, Rohit Bhargava, Craig Horbinski, Urvashi Surti, David J. Dabbs. Am J Clin Pathol. 2008;129:383-390.
  42. Mucosa-Associated Lymphoid Tissue Lymphoma of the Cervix. David Coon, Sushil Beriwal, Steven H. Swerdlow, Rohit Bhargava. J Clin Oncol. 2008;26(3):503-504.
  43. Undifferentiated Small Round Cell Sarcomas with Rare EWS Gene Fusions: Identification of a Novel EWS-SP3 Fusion and of Additional Cases with the EWS-ETV1 and EWS-FEV Fusions. Lu Wang, Rohit Bhargava, Tao Zheng, Leonard Wexler, Margaret Collins, Diane Roulston, Marc Ladanyi (LW and RB contributed equally). J Mol Diagn 2007;9:498-509.

Book Chapters:

  1. Apocrine Carcinoma. Rohit Bhargava. Textbook of Breast Pathology (Dabbs DJ, Ed), Elsevier, USA. Expected publication date Spring 2012.
  2. Molecular classification of breast carcinomas. Rohit Bhargava. Textbook of Breast Pathology (Dabbs DJ, Ed), Elsevier, USA. Expected publication date Spring 2012.
  3. Immunohistology of the Breast. Rohit Bhargava and David J Dabbs. Textbook of Breast Pathology (Dabbs DJ, Ed), Elsevier, USA. Expected publication date Spring 2012.
  4. Pathology of neoadjuvant therapeutic response of breast carcinoma. Sunati Sahoo, David J Dabbs, and Rohit Bhargava. Textbook of Breast Pathology (Dabbs DJ, Ed), Elsevier, USA. Expected publication date Spring 2012.
  5. Predictive and prognostic marker testing in breast pathology: immunophenotypic subclasses of disease. D Craig Allred, Rohit Bhargava, and David J Dabbs. Textbook of Breast Pathology (Dabbs DJ, Ed), Elsevier, USA. Expected publication date Spring 2012.
  6. Immunohistology of the Breast. Rohit Bhargava, Nicole N Esposito, David J Dabbs. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, 3rd edition (Dabbs DJ, Ed), Elsevier, USA.
  7. Immunohistology of Metastatic Carcinomas of Unknown Primary. Rohit Bhargava, and David J Dabbs. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, 3rd edition (Dabbs DJ, Ed), Elsevier, USA.
  8. Pathologic Evaluation of Metastases: Immunohistology. Rohit Bhargava (first author), Mark R Wick, David J Dabbs. Metastatic Carcinomas of Unknown Origin (Wick MR, Ed), Demos Medical Publishing, New York, 2008.



Copyright 1995-2012   
Department of Pathology   
Univ. Pittsburgh Sch. Medicine